|
[1]Geneva:World Health Organization.Guidelines for the Prevention,Care and Treatment of Persons with Chronic Hepatitis B Infection[S/OL].World Health Organization,2015[2016-08-26].https://www.ncbi.nlm.nih.gov/books/NBK305553/.
|
|
[2]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[3]TANG CM,YAU TO,YU J.Management of chronic hepatitis B infection:current treatment guidelines,challenges,and new developments[J].World J Gastroenterol,2014,20(20):6262-6278.
|
|
[4]SARIN SK,KUMAR M,LAU GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a2015 update[J].Hepatol Int,2016,10(1):1-98.
|
|
[5]TERRAULT NA,BZOWEJ NH,CHANG KM,et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology,2016,63(1):261-283.
|
|
[6]PARK JS,PAN C.Current recommendations of managing HBV infection in preconception or pregnancy[J].Front Med,2014,8(2):158-165.
|
|
[7]LUO Z,LI L,RUAN B.Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period[J].Int J Infect Dis,2012,16(2):e82-e88.
|
|
[8]ZHANG L,GUI X,WANG B,et al.A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission[J].Eur J Pediatr,2014,173(9):1161-1168.
|
|
[9]BROWN RS Jr,McM AHON BJ,LOK AS,et al.Antiviral therapy in chronic hepatitis B viral infection during pregnancy:a systematic review and meta-analysis[J].Hepatology,2016,63(1):319-333.
|
|
[10]PAN CQ,DUAN Z,DAI E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J].N Engl J Med,2016,374(24):2324-2334.
|
|
[11]BROWN RS Jr,VERNA EC,PEREIRA MR,et al.Hepatitis B virus and human immunodeficiency virus drugs in pregnancy:findings from the antiretroviral pregnancy registry[J].J Hepatol,2012,57(5):953-959.
|
|
[12]SIBERRY GK,JACOBSON DL,KALKWARF HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy[J].Clin Infect Dis,2015,61(6):996-1003.
|
|
[13]The antiretroviral pregnancy registry——interim report[R/OL].(2016-06)[2016-08-26].http://www.apregistry.com/forms/interim_report.pdf.
|
|
[14]HU Y,CHEN J,WEN J,et al.Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus[J].BMC Pregnancy Childbirth,2013,13:119.
|
|
[15] LIU CP,ZENG YL,ZHOU M,et al.Factors associated with mother-to-child transmission of hepatitis B virus despite immunoprophylaxis[J].Intern Med,2015,54(7):711-716.
|
|
[16]YANG J,ZENG XM,MEN YL,et al.Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus——a systematic review[J].Virol J,2008,5:100.
|
|
[17]PAN CQ,ZOU HB,CHEN Y,et al.Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J].Clin Gastroenterol Hepatol,2013,11(10):1349-1355.
|
|
[18]EHRHARDT S,XIE C,GUO N,et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate:a review of the evidence[J].Clin Infect Dis,2015,60(2):275-278.
|
|
[19]PETROVA M,KAMBUROV V.Breastfeeding and chronic HBV infection:clinical and social implications[J].World J Gastroenterol,2010,16(40):5042-5046.
|
|
[20] ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
|
|
[21]FUNG J,SETO WK,LAI CL,et al.Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment[J].J Gastroenterol Hepatol,2014,29(3):428-434.
|
|
[22]FONTANA RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,2009,49(5 Suppl):s185-s195.
|
|
[23]FLEISCHER RD,LOK AS.Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B[J].J Hepatol,2009,51(4):787-791.
|
|
[24]CHEN YC,SU YC,LI CY,et al.13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan[J].BMC Nephrol,2015,16:110.
|
|
[25]LIU Y,FAN R,CHEN J,et al.Assessment of renal function and risk factors for renal impairment in patients with hepatitis B virus-related liver cirrhosis[J].J South Med Univ,2014,34(4):472-476.(in Chinese)刘颖,樊蓉,陈简,等.慢性乙型肝炎病毒感染相关肝硬化患者的肾功能及危险因素分析[J].南方医科大学学报,2014,34(4):472-476.
|
|
[26]LING N,LIN WY,HU XY,et al.Prevalence of chronic kidney disease in patients with chronic hepatitis B who are on antiviral therapy:a cross-sectional survey[C].25th APASL STC,Tokyo,2016.
|
|
[27]PIPILI C,CHOLONGITAS E,PAPATHEODORIDIS G.Review article:nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].Aliment Pharmacol Ther,2014,39(1):35-46.
|
|
[28]JIA HY,DING F,CHEN JY,et al.Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B[J].World J Gastroenterol,2015,21(12):3657-3662.
|
|
[29]GANE EJ,DERAY G,LIAW YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B[J].Gastroenterology,2014,146(1):138-146,e135.
|
|
[30]LEE M,OH S,LEE HJ,et al.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy[J].J Viral Hepat,2014,21(12):873-881.
|
|
[31]CHOLONGITAS E,VASILIADIS T,GOULIS I,et al.Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease[J].J Viral Hepat,2015,22(7):574-580.
|
|
[32]HWANG JP,LOK AS.Management of patients with hepatitis B who require immunosuppressive therapy[J].Nat Rev Gastroenterol Hepatol,2014,11(4):209-219.
|
DownLoad: